Get the Stockscreener App
20.64
2.08%
0.42
After Hours:
20.80
0.16
+0.78%
Cg Oncology Inc stock is traded at $20.64, with a volume of 1.11M.
It is up +2.08% in the last 24 hours and down -25.41% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$20.22
Open:
$20.17
24h Volume:
1.11M
Relative Volume:
1.41
Market Cap:
$1.53B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-16.25
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+17.07%
1M Performance:
-25.41%
6M Performance:
-43.85%
1Y Performance:
-43.31%
1-Day Range:
$20.09
$21.16
1-Week Range:
$17.10
$21.16
52-Week Range:
$14.80
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
20.64 | 1.53B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by JPMorgan Chase & Co. - Defense World
CG Oncology (NASDAQ:CGON) Coverage Initiated at Scotiabank - Defense World
Geode Capital Management LLC Has $33.18 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology initiated with a Sector Perform at Scotiabank - TipRanks
Scotiabank Initiates Coverage of CG Oncology (CGON) with Sector Perform Recommendation - Nasdaq
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target - marketscreener.com
CG Oncology (CGON) vs. Its Competitors Financial Comparison - Defense World
KLP Kapitalforvaltning AS Takes $100,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Rating of “Buy” from Analysts - Defense World
CG Oncology stock hits 52-week low at $15.7 amid market challenges - Investing.com UK
CG Oncology’s SWOT analysis: bladder cancer stock races against competition By Investing.com - Investing.com South Africa
CG Oncology's SWOT analysis: bladder cancer stock races against competition - Investing.com
CG Oncology’s SWOT analysis: bladder cancer stock races against competition - Investing.com India
CG Oncology's SWOT analysis: bladder cancer stock races against competition By Investing.com - Investing.com South Africa
Vanguard Group Inc. Has $168.10 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Reviewing CG Oncology (CGON) and Its Competitors - Defense World
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Q1 Earnings Estimate for CG Oncology Issued By HC Wainwright - Defense World
Cantor Fitzgerald Weighs in on CG Oncology FY2025 Earnings - Defense World
HC Wainwright Forecasts CG Oncology FY2029 Earnings - Defense World
CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (NASDAQ:CGON) - Seeking Alpha
Teacher Retirement System of Texas Acquires Shares of 11,927 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Relative Strength Alert For CG Oncology - Nasdaq
CG Oncology stock hits 52-week low at $23.9 amid challenges - Investing.com UK
CG Oncology (NASDAQ:CGON) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright maintains CG Oncology stock Buy rating, $75 target By Investing.com - Investing.com Canada
Practice-Changing Bladder Cancer Results: Key BOND-003 Trial Data Revealed at Major Urology Conference - Stock Titan
CG Oncology announces mixed shelf offering - MSN
CG Oncology Advances in Bladder Cancer Therapeutics - MSN
CG Oncology Full Year 2024 Earnings: Misses Expectations - Yahoo
CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing - MarketScreener
CG Oncology, Inc. SEC 10-K Report - TradingView
CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates - Marketscreener.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - The Manila Times
Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains CG Oncology buy with $75 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains CG Oncology buy with $75 target - Investing.com India
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts - Benzinga
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial - Marketscreener.com
Cretostimogene shows promise in bladder cancer study By Investing.com - Investing.com Australia
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News
Cretostimogene shows promise in bladder cancer study - Investing.com India
CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment - Nasdaq
Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Decreases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CG Oncology (NASDAQ:CGON) Stock Price Up 7.3% – Time to Buy? - Defense World
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):